Xiaodong Wang Sells 900 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) insider Xiaodong Wang sold 900 shares of the stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $250.00, for a total transaction of $225,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Xiaodong Wang also recently made the following trade(s):

• On Wednesday, January 11th, Xiaodong Wang sold 2,500 shares of BeiGene stock. The stock was sold at an average price of $252.66, for a total transaction of $631,650.00.
• On Tuesday, December 13th, Xiaodong Wang sold 3,013 shares of BeiGene stock. The stock was sold at an average price of $211.33, for a total transaction of $636,737.29.
• On Tuesday, November 15th, Xiaodong Wang sold 1,987 shares of BeiGene stock. The stock was sold at an average price of $210.14, for a total transaction of $417,548.18.

BeiGene Trading Up 3.5 %

BeiGene stock opened at $263.23 on Friday. The firm has a 50 day simple moving average of $207.90 and a 200-day simple moving average of $181.52. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.07 and a quick ratio of 3.87. The stock has a market capitalization of $27.34 billion, a PE ratio of -12.33 and a beta of 0.78. BeiGene, Ltd. has a 12-month low of $118.18 and a 12-month high of $263.97.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in shares of BeiGene by 2.4% in the third quarter. Bank of New York Mellon Corp now owns 57,839 shares of the company’s stock valued at $7,798,000 after acquiring an additional 1,348 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of BeiGene by 6.2% in the third quarter. California State Teachers Retirement System now owns 12,855 shares of the company’s stock valued at $1,733,000 after acquiring an additional 751 shares in the last quarter. Baird Financial Group Inc. lifted its stake in BeiGene by 5.9% during the third quarter. Baird Financial Group Inc. now owns 103,576 shares of the company’s stock valued at $13,964,000 after purchasing an additional 5,804 shares during the last quarter. BNP Paribas Arbitrage SNC lifted its stake in BeiGene by 14.0% during the third quarter. BNP Paribas Arbitrage SNC now owns 72,046 shares of the company’s stock valued at $9,713,000 after purchasing an additional 8,853 shares during the last quarter. Finally, Colony Group LLC acquired a new stake in BeiGene during the third quarter valued at approximately $1,373,000. 51.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BGNE has been the subject of several recent analyst reports. Cowen upped their target price on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. Guggenheim upped their target price on shares of BeiGene to $210.00 in a research report on Tuesday, November 15th. Cowen upped their target price on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. Daiwa Capital Markets initiated coverage on shares of BeiGene in a research report on Wednesday. They issued a “buy” rating and a $308.00 target price for the company. Finally, Morgan Stanley upped their target price on shares of BeiGene from $290.00 to $295.00 and gave the stock an “overweight” rating in a research report on Thursday, October 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, BeiGene presently has an average rating of “Moderate Buy” and a consensus target price of $253.00.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).